This course has expired. View available courses.
Dermatology
Challenging cases in plaque psoriasis – optimising outcomes
This 1-hour RACP accredited activity program is designed to provide dermatologists with a contemporary clinical approach to the management of plaque psoriasis, with the aim of optimising outcomes for their patients. The program will help dermatologists explore the efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis.
This educational activity was developed by MdBriefCase at the request, and with funding from Eli Lilly.
DURATION
1.0 hr
PROFESSION
Specialist
# OF CREDITS
1
ACCREDITATION
RACP
EXPIRY DATE
2022-12-31
This 1-hour RACP accredited activity program is designed to provide dermatologists with a contemporary clinical approach to the management of plaque psoriasis, with the aim of optimising outcomes for their patients. The program will help dermatologists explore the efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis.
This educational activity was developed by MdBriefCase at the request, and with funding from Eli Lilly.
Faculty
Prof. Peter Foley,
BMedSc, MBBS, MD, FACD
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the advantages in pursuing a treatment plan with a goal of achieving a Psoriasis Area Severity Index (PASI) 100 response
- Evaluate efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis
- Identify patients with plaque psoriasis who would most benefit from treatment with ixekizumab
Accreditation
This interactive online learning activity is valued at 1 Hour(s) of continuing education with RACP.
#
of credits: 1
Duration: 1.0 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1.0 hr
Duration
Specialist
Profession
1
# of credits
Learning Objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the advantages in pursuing a treatment plan with a goal of achieving a Psoriasis Area Severity Index (PASI) 100 response
- Evaluate efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis
- Identify patients with plaque psoriasis who would most benefit from treatment with ixekizumab
RACP
ACCREDITATION
Dermatology
Learning Category
Psoriasis
Topic
0
Price
2022-12-31
Expiry Date
AUS
Region/Language
Course Description
This 1-hour RACP accredited activity program is designed to provide dermatologists with a contemporary clinical approach to the management of plaque psoriasis, with the aim of optimising outcomes for their patients. The program will help dermatologists explore the efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis.
This educational activity was developed by MdBriefCase at the request, and with funding from Eli Lilly.
Faculty
Prof. Peter Foley,
BMedSc, MBBS, MD, FACD
Accreditation
This interactive online learning activity is valued at 1 Hour(s) of continuing education with RACP.
1.0 hr
Duration
0
Price
1
# of credits
